IL125060A - 4-substituted piperidine analogs, process for their preparation and pharmaceutical compositions containing them for use as subtype selective nmda receptor antagonists - Google Patents

4-substituted piperidine analogs, process for their preparation and pharmaceutical compositions containing them for use as subtype selective nmda receptor antagonists

Info

Publication number
IL125060A
IL125060A IL12506096A IL12506096A IL125060A IL 125060 A IL125060 A IL 125060A IL 12506096 A IL12506096 A IL 12506096A IL 12506096 A IL12506096 A IL 12506096A IL 125060 A IL125060 A IL 125060A
Authority
IL
Israel
Prior art keywords
substituted piperidine
piperidine analogs
pct
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL12506096A
Other languages
English (en)
Other versions
IL125060A0 (en
Original Assignee
Warner Lambert Co
Cocensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Cocensys Inc filed Critical Warner Lambert Co
Publication of IL125060A0 publication Critical patent/IL125060A0/xx
Publication of IL125060A publication Critical patent/IL125060A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
IL12506096A 1995-12-22 1996-12-20 4-substituted piperidine analogs, process for their preparation and pharmaceutical compositions containing them for use as subtype selective nmda receptor antagonists IL125060A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US919295P 1995-12-22 1995-12-22
PCT/US1996/020766 WO1997023214A1 (en) 1995-12-22 1996-12-20 4-substituted piperidine analogs and their use as subtype selective nmda receptor antagonists

Publications (2)

Publication Number Publication Date
IL125060A0 IL125060A0 (en) 1999-01-26
IL125060A true IL125060A (en) 2003-07-31

Family

ID=21736135

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12506096A IL125060A (en) 1995-12-22 1996-12-20 4-substituted piperidine analogs, process for their preparation and pharmaceutical compositions containing them for use as subtype selective nmda receptor antagonists

Country Status (22)

Country Link
US (4) US6130234A (de)
EP (1) EP0869791B1 (de)
JP (1) JP2000502352A (de)
AT (1) ATE239473T1 (de)
AU (1) AU719430B2 (de)
BG (1) BG63424B1 (de)
BR (1) BR9612153A (de)
CA (1) CA2240038A1 (de)
CZ (1) CZ177898A3 (de)
DE (1) DE69628035T2 (de)
DK (1) DK0869791T3 (de)
EA (1) EA001133B1 (de)
ES (1) ES2196196T3 (de)
IL (1) IL125060A (de)
MX (1) MX9805032A (de)
NO (1) NO312028B1 (de)
NZ (1) NZ325735A (de)
PL (1) PL327413A1 (de)
PT (1) PT869791E (de)
SK (1) SK82398A3 (de)
WO (1) WO1997023214A1 (de)
ZA (1) ZA9610741B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
AU4424697A (en) * 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity
GB9704948D0 (en) * 1997-03-11 1997-04-30 Knoll Ag Therapeutic agents
EP1024799A1 (de) 1997-10-24 2000-08-09 Warner-Lambert Company Verfahren zur behandlung von krankheitsbedingten oder arzneistoff induzierten dyskinesien
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
PE20000728A1 (es) * 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US20060025387A1 (en) * 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US6316474B1 (en) * 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
CA2419159A1 (en) * 2000-08-11 2002-02-21 Agilix Corporation Ultra-sensitive detection systems
EP1186303A3 (de) * 2000-09-06 2003-12-10 Pfizer Products Inc. Ein Neutrophilhemmender Faktor und ein selektive NMDA-NR2B Rezeptor Antagonisten enthaltende Kombinationspräparate zur Behandlung von Schlaganfällen und traumatischen Gehirnschäden
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
EP1674087A1 (de) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylaktische Verwendung von N-Methyl-D-Aspartat Rezeptor (NMDA) Antagonisten
MXPA03004652A (es) 2000-12-21 2003-09-05 Warner Lambert Co Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato.
CA2453383C (en) 2001-07-24 2010-04-06 Richter Gedeon Vegyeszeti Gyar Rt Piperidine derivatives as nmda receptor antagonists
ATE327673T1 (de) * 2001-08-23 2006-06-15 Bayer Cropscience Sa Substituierte propargylamine
JPWO2003035641A1 (ja) * 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体
CA2466861A1 (en) * 2001-11-06 2003-07-10 Agilix Corporation Sensitive coded detection systems
DE10201550A1 (de) * 2002-01-17 2003-07-31 Merck Patent Gmbh Phenoxy-Piperidine
WO2005037286A1 (en) * 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
CA2596117A1 (en) * 2005-02-03 2006-08-10 Perkinelmer Las, Inc. Ultra-sensitive detection systems using multidimension signals
KR101396731B1 (ko) 2005-03-31 2014-05-19 산텐 세이야꾸 가부시키가이샤 프로스타글란딘 Ｆ２ａ 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
CN101160128B (zh) * 2005-04-13 2010-08-18 宇部兴产株式会社 含有吲唑衍生物作为有效成分的视网膜神经细胞保护剂
CN101213187B (zh) 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 作为rho-激酶抑制剂的异喹啉衍生物
CA2615577C (en) 2005-07-26 2014-09-09 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
RS52241B (sr) 2005-07-26 2012-10-31 Sanofi Derivati cikloheksilamin izohinolona kao inhibitori rho-kinaze
JP2009511629A (ja) * 2005-10-17 2009-03-19 ニューロセラピューティクス ファーマ， インコーポレイテッド 中枢神経系疾患の調節に有用な利尿薬様化合物類似体
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5421783B2 (ja) 2006-12-27 2014-02-19 サノフイ Ｒｈｏキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体
RU2468011C2 (ru) 2006-12-27 2012-11-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолина и изохинолинона
MY148902A (en) 2006-12-27 2013-06-14 Sanofi Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
BRPI0720986A2 (pt) 2006-12-27 2014-03-11 Sanofi Aventis Derivados de isoquinolina e isoquinolinona substituídos
MX2009005964A (es) 2006-12-27 2009-06-15 Sanofi Aventis Derivados de isoquinolina sustituidos con cicloalquilamina.
NZ577980A (en) 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (de) 2007-04-18 2014-12-24 Probiodrug AG Thioharnstoffderivate als glutaminylcyclaseinhibitoren
MY153615A (en) 2008-06-24 2015-02-27 Sanofi Aventis 6-substituted isoquinolines and isoquinolinones
MY153756A (en) 2008-06-24 2015-03-13 Sanofi Aventis Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors
CA2728137C (en) 2008-06-24 2016-10-18 Sanofi-Aventis Substituted isoquinolines and isoquinolinones as rho kinase inhibitors
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (de) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazolderivate als glutaminylcyclase-hemmer
EP2705024B1 (de) * 2011-05-03 2015-12-16 Merck Sharp & Dohme Corp. Alkin-Benzotriazol-Derivate
RU2638807C2 (ru) 2011-11-22 2017-12-15 Те Риджентс Оф Те Юниверсити Оф Калифорния Способы и композиции для лечения воспаления и ишемического поражения
WO2015103183A1 (en) * 2014-01-02 2015-07-09 Jasper John P Method for continuously monitoring chemical or biological processes
WO2017041095A1 (en) * 2015-09-03 2017-03-09 Allegheny-Singer Research Institute Hydrophilic fentanyl derivatives
SI25272A (sl) * 2016-09-23 2018-03-30 Univerza V Ljubljani Disubstituirani azetidini, pirolidini, piperidini in azepani kot zaviralci monoamin oksidaze B za zdravljenje nevrodegenerativnih bolezni
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN108250058B (zh) 2018-01-19 2022-02-11 上海怡立舍生物技术有限公司 Ppar激动剂及其在治疗老年痴呆及其他疾病中的用途
WO2022251280A1 (en) * 2021-05-25 2022-12-01 Vividion Therapeutics, Inc. Compounds selective for jak1 and methods of use

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3255196A (en) 1966-06-07 Phenoxyalkyl piperidine derivatives
CA696999A (en) 1964-11-03 Ayerst, Mckenna And Harrison Therapeutic compounds and their preparation
GB1052302A (de) * 1963-04-22
GB1055548A (en) 1965-08-23 1967-01-18 Acraf New substituted 1-aryl-3-aminopropynes and process for their preparation
US3632767A (en) 1968-02-12 1972-01-04 Mallinckrodt Chemical Works Treatment of depression with 4-substituted piperidines
US3686187A (en) * 1970-05-25 1972-08-22 Abbott Lab 4-anilino-1-(4-p-fluorophenyl-1-butyl) piperidine compounds
AR206937A1 (es) * 1974-09-06 1976-08-31 Lilly Co Eli Procedimiento para preparar compuestos de 1-sustituido-4-alquil-4-fenil-piperidina
DE2651574A1 (de) 1976-11-12 1978-05-18 Boehringer Mannheim Gmbh Ein neues aminopropanol-derivat und verfahren zu dessen herstellung
US4312876A (en) * 1979-02-23 1982-01-26 Hoechst-Roussel Pharmaceuticals Incorporated Antidepressive and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines
GB2056435A (en) * 1979-06-26 1981-03-18 Ciba Geigy Ag Novel Tetrahydropyridine and Piperidine Substituted Benzofuranes and Related Compounds
DE2939292A1 (de) 1979-09-28 1981-04-09 Boehringer Mannheim Gmbh, 6800 Mannheim N-phenoxyalkylpiperidin-derivate, verfahrenn zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
US4577020A (en) * 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3421641A1 (de) * 1984-06-09 1985-12-12 Merck Patent Gmbh, 6100 Darmstadt Indolderivate
JPS61115068A (ja) 1984-11-08 1986-06-02 Hokuriku Seiyaku Co Ltd ４−ベンジルピペリジニルプロポキシアニリン誘導体
US4567186A (en) * 1985-01-14 1986-01-28 Sterling Drug Inc. 5-Heteryl-1,6-naphthyridin-2(1H)-ones, cardiotonic use thereof and intermediates therefor
JPH0615529B2 (ja) 1985-04-01 1994-03-02 エーザイ株式会社 新規ピペリジン誘導体
EP0228893A3 (de) 1985-12-20 1990-01-03 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Durch Aryloxyalkyl-Gruppen N-substituierte Arylalkyl heterozyklische Amine in Allergieheilverfahren
DK623586A (da) 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
KR910006138B1 (ko) 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
DE3703435A1 (de) 1987-02-05 1988-08-18 Thomae Gmbh Dr K Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
FR2620704B1 (fr) 1987-09-17 1991-04-26 Sanofi Sa Derives de (benzyl-4 piperidino)-1 propanol-2, leur preparation, leur utilisation comme antimicrobiens et les produits les contenant
EP0424525B1 (de) 1987-12-11 1994-12-21 Mitsui Petrochemical Industries, Ltd. Amine und deren verwendung
ZA891901B (en) 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy
FR2640266B2 (fr) 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5011834A (en) 1989-04-14 1991-04-30 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
EP0398578B1 (de) 1989-05-17 1997-03-12 Pfizer Inc. 2-Piperidino-1-alkanol-Derivate als antiischemische Wirkstoffe
ZA908641B (en) 1989-10-27 1992-06-24 Du Pont (n-phthalimidoalkyl)piperidines
US5149817A (en) 1990-03-05 1992-09-22 Shionogi & Co., Ltd. Teirahydropyridine derivatives
US5116846A (en) 1990-03-28 1992-05-26 Du Pont Merck Pharmaceutical Company N-aralkyl piperidine derivatives as psychotropic drugs
US5169855A (en) 1990-03-28 1992-12-08 Du Pont Merck Pharmaceutical Company Piperidine ether derivatives as psychotropic drugs or plant fungicides
WO1991017156A1 (en) 1990-05-10 1991-11-14 Pfizer Inc Neuroprotective indolone and related derivatives
JPH04217945A (ja) 1990-07-18 1992-08-07 Zeria Pharmaceut Co Ltd 置換アルキルベンゼン誘導体およびそれを含有する抗潰瘍剤
IE912759A1 (en) 1990-08-06 1992-02-12 Smith Kline French Lab Compounds
FR2668149B1 (fr) 1990-10-18 1994-09-23 Synthelabo Le 1-(3,4-dihydro-2-oxo-1h-quinolein-6-yl)-2-[4-(2-phenyl-ethyl)piperidin-1-yl]ethanol, sa preparation et son application en therapeutique.
US5273977A (en) 1990-11-05 1993-12-28 Warner-Lambert Company Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
US5270312A (en) * 1990-11-05 1993-12-14 Warner-Lambert Company Substituted piperazines as central nervous system agents
EP0488959A3 (en) 1990-11-28 1992-08-05 Sandoz Ltd. New uses of competitive nmda receptor antagonists
JPH04312572A (ja) 1991-04-12 1992-11-04 Takeda Chem Ind Ltd 環状アミン化合物
US5231099A (en) 1991-04-15 1993-07-27 Du Pont Merck Pharmaceutical Company Use of sigma receptor antagonists to enhance the effects of antipsychotic drugs
EP0524846A1 (de) 1991-06-27 1993-01-27 Synthelabo 2-(Piperidin-1-yl)ethanolderivate, ihre Herstellung und ihre Anwendung in der Therapie
AU676993B2 (en) 1991-06-27 1997-04-10 Virginia Commonwealth University Sigma receptor ligands and the use thereof
EP0594729A1 (de) 1991-07-17 1994-05-04 Pfizer Inc. 2-(4-hydroxypiperidino)-1-alkanolderivate als anti-ischämische wirkstoffe
FR2681319B1 (fr) 1991-09-12 1995-02-17 Synthelabo Derives de 1-(phenoxyalkyl)piperidine, leur preparation et leur application en therapeutique.
HU211019B (en) 1991-12-02 1995-09-28 Richter Gedeon Vegyeszet Process for producing new 1,2,3,6-tetrahydropyridine and piperidine derivatives substituted with n-(hydroxylalkyl) group and compositions comprising such compounds
WO1993015052A1 (en) 1992-01-28 1993-08-05 Smithkline Beecham Plc Compounds as calcium channel antagonists
US5202346A (en) 1992-02-25 1993-04-13 American Home Products Corporation Piperidinyl and piperazinyl derivatives
ES2060547B1 (es) 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
DK0666854T3 (da) 1992-10-30 1997-04-28 Pfizer Neurobeskyttende 3,4-dihydro-2(1H)-quinolon forbindelser
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
WO1994018172A1 (fr) 1993-02-01 1994-08-18 Yoshitomi Pharmaceutical Industries, Ltd. Compose d'imidazolylbenzene et son utilisation comme medicament
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
TW281670B (de) 1993-09-02 1996-07-21 Hoffmann La Roche
CN1154640C (zh) * 1993-10-01 2004-06-23 纽约市哥伦比亚大学理事 用标示物编码的多元组合化学库
DE4335718A1 (de) 1993-10-20 1995-04-27 Merck Patent Gmbh Cyclische Aminderivate
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
US5549974A (en) * 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof

Also Published As

Publication number Publication date
MX9805032A (es) 1998-11-30
NZ325735A (en) 2000-02-28
EP0869791A4 (de) 1999-04-28
IL125060A0 (en) 1999-01-26
EP0869791A1 (de) 1998-10-14
DE69628035D1 (de) 2003-06-12
CZ177898A3 (cs) 1998-12-16
ZA9610741B (en) 1997-06-24
PT869791E (pt) 2003-08-29
PL327413A1 (en) 1998-12-07
SK82398A3 (en) 1999-03-12
US20030100018A1 (en) 2003-05-29
ES2196196T3 (es) 2003-12-16
EA199800591A1 (ru) 1999-02-25
ATE239473T1 (de) 2003-05-15
NO982869L (no) 1998-08-24
AU719430B2 (en) 2000-05-11
US6130234A (en) 2000-10-10
BG63424B1 (bg) 2002-01-31
NO312028B1 (no) 2002-03-04
DE69628035T2 (de) 2004-02-12
NO982869D0 (no) 1998-06-19
AU1431097A (en) 1997-07-17
BR9612153A (pt) 1999-12-28
US6448270B1 (en) 2002-09-10
BG102561A (en) 1999-04-30
CA2240038A1 (en) 1997-07-03
EP0869791B1 (de) 2003-05-07
JP2000502352A (ja) 2000-02-29
US20030105133A1 (en) 2003-06-05
WO1997023214A1 (en) 1997-07-03
DK0869791T3 (da) 2003-06-10
EA001133B1 (ru) 2000-10-30

Similar Documents

Publication Publication Date Title
IL125060A (en) 4-substituted piperidine analogs, process for their preparation and pharmaceutical compositions containing them for use as subtype selective nmda receptor antagonists
IL125061A0 (en) 4-substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
PL328816A1 (en) Novel substituted cyclic amino acids as pharmaceutic agents
WO1999026927A3 (en) Metabotropic glutamate receptor antagonists for treating central nervous system diseases
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
EP1622914A4 (de) Neue piperidinylaminothieno¬2,3-d pyrimidinverbindungen
PA8535901A1 (es) Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato
FI964340A0 (fi) Uudet asykliset ja sykliset amidit hermoston välittäjäaineen vapautumisen tehostimina
GR3033528T3 (en) Novel piperidine derivatives with paf antagonist activity
DE69803458D1 (de) Tricyclisch substituierte 2,4-Dithi(oxo)-pyrimidin-5-yl-Verbindungen als P2- Purinoceptor-Antagonisten
US7348340B2 (en) N-type calcium channel antagonists for the treatment of pain
JPWO2019163917A1 (ja) Ｓ１ｐ５受容体作動活性を有する化合物
GR3034354T3 (en) IMIDAZO 1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
GR3036195T3 (en) Novel compounds
PL327461A1 (en) Novel derivatives of piperazine alkylthiopyrimidines, pharmaceutic compositions containing such compounds and method of obtaining novel compounds

Legal Events

Date Code Title Description
HK Corrigendum

Free format text: P. 1536 PATENT APPLICATION NO. 125060 CORRECT CONVENTION COUNTRY TO- US

FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees